We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.
- Authors
Giorgini, Flaviano; Guidetti, Paolo; Nguyen, QuangVu; Bennett, Simone C; Muchowski, Paul J
- Abstract
Huntington disease is a fatal neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein huntingtin (Htt), which leads to its aggregation in nuclear and cytoplasmic inclusion bodies. We recently identified 52 loss-of-function mutations in yeast genes that enhance the toxicity of a mutant Htt fragment. Here we report the results from a genome-wide loss-of-function suppressor screen in which we identified 28 gene deletions that suppress toxicity of a mutant Htt fragment. The suppressors are known or predicted to have roles in vesicle transport, vacuolar degradation, transcription and prion-like aggregation. Among the most potent suppressors was Bna4 (kynurenine 3-monooxygenase), an enzyme in the kynurenine pathway of tryptophan degradation that has been linked directly to the pathophysiology of Huntington disease in humans by a mechanism that may involve reactive oxygen species. This finding is suggestive of a conserved mechanism of polyglutamine toxicity from yeast to humans and identifies new candidate therapeutic targets for the treatment of Huntington disease.
- Subjects
LEAVENING agents; NEURODEGENERATION; GENOMES; HUNTINGTON disease; THERAPEUTICS; KYNURENINE; TRYPTOPHAN
- Publication
Nature Genetics, 2005, Vol 37, Issue 5, p526
- ISSN
1061-4036
- Publication type
Article
- DOI
10.1038/ng1542